
Canadian Natural to buy Advantage in $2.53 billion deal
Key points
- Canadian Natural Resources (NYSE:CNQ) agreed to acquire Advantage Energy in a transaction valued at approximately C$2.53 billion.
- The deal adds approximately 79,000 barrels of oil equivalent per day (BOE/d) of Montney and Charlie Lake production and development assets.
- Canadian Natural expects the acquisition to be accretive and generate operating efficiencies while maintaining its policy of allocating 100% of free cash flow to share repurchases, subject to market conditions.
Canadian Natural Resources (NYSE:CNQ) signed a definitive agreement to acquire Advantage Energy in a transaction valued at approximately $2.53 billion, adding around 79,000 BOE/d of production.
The acquisition covers Advantage's Montney and Charlie Lake assets in Alberta, including producing operations and development inventory located adjacent to Canadian Natural's existing Grande Prairie operations.
Canadian Natural said it expects the acquisition to be accretive and generate scale efficiencies by integrating the acquired assets with its existing operations.
The cash offer is $13.55 per Advantage share, representing approximately $2.255 billion in fully diluted equity value, while the total transaction value includes Advantage's net debt and outstanding convertible debentures.
Canadian Natural will fund the acquisition using cash on hand and existing bank credit facilities, while maintaining its target of allocating 100% of free cash flow to share repurchases, subject to market conditions.
The transaction values the acquired production at approximately $32,000 per flowing BOE/d and is targeted to close in the first quarter of 2027, subject to customary closing conditions and regulatory approvals.
Frequently asked questions
More from United States
Cytokinetics adds Phase 3 data to MYQORZO label
Niu Technologies reveals RMB1.7 billion Q3 revenue
iQIYI narrows losses as revenue falls 10%
Baidu reports RMB1.4 billion third-quarter profit
Aclaris starts 100-patient modzatinib lichen planus trial
Aclaris bosakitug misses both endpoints in 109-patient trial

